Back to discover
Disease

congenital factor X deficiency

Also known as Stuart-Prower factor deficiency, congenital Stuart factor deficiency, disease, Stuart-Prower, hereditary Factor X deficiency+6 more

Stuart-Prower factor deficiency, congenital Stuart factor deficiency, disease, Stuart-Prower, hereditary Factor X deficiency, F10 deficiency, Stuart factor deficiency, congenital, Stuart-Prower Factor deficiency, factor 10 deficiency, factor X deficiency, factor X deficiency, congenital.

1
Associated genes
1
Related proteins

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

No activity recorded in this window. Try a wider timeframe.

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Concizumabapproved

Approval — Alhemo is indicated for routine prophylaxis of bleeding in patients 12 years of age or mo… (2024)

Marstacimabapproved

Approval — Hympavzi is indicated for routine prophylaxis of bleeding episodes in patients 12 years o… (2024)

Etranacogene dezaparvovecapproved

Approval — Treatment of severe and moderately severe Haemophilia B (congenital Factor IX deficiency)… (2023)

Valoctocogene roxaparvovecapproved

Approval — Treatment of severe haemophilia A (congenital factor VIII deficiency) in adult patients w… (2022)

Turoctocog alfa pegolapproved

Approval — Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor V… (2019)

Damoctocog alfa pegolapproved

Approval — Treatment and prophylaxis of bleeding in previously treated patients (PTPs) ≥ 7 years of… (2018)

Emicizumabapproved

Accelerated approval — Hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemo… (2018)

Metreleptinapproved

Approval — Myalepta is indicated as an adjunct to diet as a replacement therapy to treat the complic… (2018)

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2024emaApproval — Concizumab· Alhemo is indicated for routine prophylaxis of bleeding in patients 12 years of age or more with: •    haemophilia A (congenital factor VIII deficiency) with FVIII inhibitors.•    severe haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without FVIII inhibitors.•    haemophilia B (congenital factor IX deficiency) with FIX inhibitors.•    moderate/severe haemophilia B (congenital factor IX deficiency, FIX ≤ 2%) without FIX inhibitors. source ↗
2024emaApproval — Marstacimab· Hympavzi is indicated for routine prophylaxis of bleeding episodes in patients 12 years of age and older, weighing at least 35 kg, with: severe haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without factor VIII inhibitors, or severe haemophilia B (congenital factor IX deficiency, FIX < 1%) without factor IX inhibitors. source ↗
2023emaApproval — Etranacogene dezaparvovec· Treatment of severe and moderately severe Haemophilia B (congenital Factor IX deficiency) in adult patients without a history of Factor IX inhibitors. source ↗
2022emaApproval — Valoctocogene roxaparvovec· Treatment of severe haemophilia A (congenital factor VIII deficiency) in adult patients without a history of factor VIII inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (AAV5). source ↗
2019emaApproval — Turoctocog alfa pegol· Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).Esperoct can be used for all age groups. source ↗
2018emaApproval — Damoctocog alfa pegol· Treatment and prophylaxis of bleeding in previously treated patients (PTPs) ≥ 7 years of age with haemophilia A (congenital factor VIII deficiency). source ↗
2018emaApproval — Metreleptin· Myalepta is indicated as an adjunct to diet as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy (LD) patients: with confirmed congenital generalised LD (Berardinelli-Seip syndrome) or acquired generalised LD (Lawrence syndrome) in adults and children 2 years of age and above with confirmed familial partial LD or acquired partial LD (Barraquer-Simons syndrome), in adults and children 12 years of age and above for whom standard treatments have failed to achieve adequate metabolic control. source ↗
2018emaAccelerated approval — Emicizumab· Hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia A (congenital factor VIII deficiency): with factor VIII inhibitors without factor VIII inhibitors who have: severe disease (FVIII < 1%) moderate disease (FVIII ? 1% and ? 5%) with severe bleeding phenotype. Hemlibra can be used in all age groups. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Associated genes

1 match

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

F100.73

Disease biology

1 match

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Coagulation factor Xvia F100.73

Reference

Authoritative identity, definition & identifiers.

Synonyms

Stuart-Prower factor deficiency, congenital Stuart factor deficiency, disease, Stuart-Prower, hereditary Factor X deficiency, F10 deficiency, Stuart factor deficiency, congenital, Stuart-Prower Factor deficiency, factor 10 deficiency, factor X deficiency, factor X deficiency, congenital

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.